Trials / Terminated
TerminatedNCT01069796
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- ARCAGY/ GINECO GROUP · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel | 80 mg/m² weekly |
| DRUG | Bevacizumab | 10 mg/kg d1 d15 |
| DRUG | Capecitabine | 800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3 |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-03-01
- Completion
- 2014-06-01
- First posted
- 2010-02-17
- Last updated
- 2016-03-17
Locations
17 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01069796. Inclusion in this directory is not an endorsement.